RHHBY Roche announces positive Phase 2 results for dual GLP-1/GIP receptor agonist Enicepatide in people living with type 2 diabetes and overweight or obesity. At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 wks
RHHBY Roche announces positive Phase 2 results for dual GLP-1/GIP receptor agonist Enicepatide in people living with type 2 diabetes and overweight or obesity. At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 wks